Administration of CCK, in humans and animals, inhibits food intake by reducing meal size and its duration.17,18 Recent work suggests that CCK-A receptors expressed by vagal afferent neurons are an important target for CCK in producing sensations of satiety, as well as inhibiting gastric emptying and stimulating pancreatic digestive enzyme secretion.19 In animals it is thought that the reduction in food intake may be mediated by a paracrine/neurocrine effect since high concentrations of CCK occur only locally to the site of release.20 Thus, locally released CCK may increase vagal tone, without a significant increase in plasma CCK level
urgent medical attention is needed for chest pain, severe upper abdominal pain, or symptoms suggesting pancreatitis or cardiovascular events
The severity and type of gastrointestinal symptoms vary considerably between individuals and between different GLP-1 medications
doi: 10.1016/j.tem.2023.10.005 10 TangRZhongTLeiKLinXLiX
It is also worth examining closely, because the science of getting a GLP-1 molecule through your skin is far less forgiving than the marketing suggests
